Lumos Pharma (Lumos Pharma) FCF Margin % : -895.04% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lumos Pharma's Free Cash Flow for the three months ended in Dec. 2023 was $-7.39 Mil. Lumos Pharma's Revenue for the three months ended in Dec. 2023 was $0.83 Mil. Therefore, Lumos Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was -895.04%.

As of today, Lumos Pharma's current FCF Yield % is -145.67%.

The historical rank and industry rank for Lumos Pharma's FCF Margin % or its related term are showing as below:

LUMO' s FCF Margin % Range Over the Past 10 Years
Min: -13706.55 Med: -304.2 Max: 62.21
Current: -1134.03

During the past 13 years, the highest FCF Margin % of Lumos Pharma was 62.21%. The lowest was -13706.55%. And the median was -304.20%.

LUMO's FCF Margin % is ranked worse than
77.27% of 1047 companies
in the Biotechnology industry
Industry Median: -145.04 vs LUMO: -1134.03

Lumos Pharma FCF Margin % Historical Data

The historical data trend for Lumos Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma FCF Margin % Chart

Lumos Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-13,706.55

-12,903.48

-1,749.44

-1,516.09

Lumos Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-1,137.89	-1,330.97	-548.85	-111,714.29	-895.04

Competitive Comparison of Lumos Pharma's FCF Margin %

For the Biotechnology subindustry, Lumos Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lumos Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lumos Pharma's FCF Margin % falls into.

Lumos Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lumos Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-31.095	/	2.051
	=	-1,516.09 %

Lumos Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.393	/	0.826
	=	-895.04 %

Lumos Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Pharma (Lumos Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (NAS:LUMO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756

Website

https://www.lumos-pharma.com

Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Executives

David B Karpf	officer: Chief Medical Officer	1360 WILLOW ROAD #100, MENLO PARK CA 94025
Aaron Schuchart	officer: Chief Business Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S.MOPAC EXPWY,BARTONOAKSPLAZONE,#250, AUSTIN TX 78746
Es-johansson An Van	director	6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Joseph S Mccracken	director	C/O NEXVET BIOPHARMA PLC, NATL INST, FOSTERS AVENUE, MOUNT MERRION, BLACKROCK L2 00000
Richard J Hawkins	director, officer: Chief Executive Officer	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Emmett Cunningham	director	C/O RESTORATION ROBOTICS, INC., 128 BAYTECH DRIVE, SAN JOSE CA 95134
Kevin M. Lalande	director	201 WEST 5TH STREET, AUSTIN TX 78701
John C. Mckew	officer: Chief Scientific Officer	C/O LUMOS PHARMA, 4200 MARATHON BLVD, STE 200, AUSTIN TX 78756
Deerfield Mgmt Iii, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iii, L.p.	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C)	10 percent owner, other: Possible Member of 10% Group	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Bradley J Powers	officer: Principal Executive Officer	C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Lori D Lawley	officer: Principal Accounting Officer	C/O NEWLINK GENETICS CORPORATION, 2503 SOUTH LOOP DRIVE, AMES IA 50010
Ernest Iii Talarico	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010